Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.

US pharma giant Eli Lilly has ventured into India with an anti-obesity and diabetes drug called Mounjaro. This development comes after the drug’s approval from the Central Drugs Standard Control Organisation (CDSCO).

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover advantage in a market